Welcome to our dedicated page for American Vanguard SEC filings (Ticker: AVD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The American Vanguard Corporation (NYSE: AVD) SEC filings page on Stock Titan provides structured access to the company’s regulatory disclosures, alongside AI-powered tools that help interpret complex documents. As a diversified specialty and agriculture products company, American Vanguard files periodic and current reports that describe its financial condition, operations, and material events.
Investors can review Form 10-K annual reports and Form 10-Q quarterly reports to see detailed discussions of net sales by U.S. crop, U.S. non-crop, and international categories, cost of sales, gross profit, operating expenses, research and product development spending, and transformation-related items. These filings also present information on debt levels, inventory, net working capital, and other balance sheet metrics that management frequently references in earnings releases.
The company’s Form 8-K current reports highlight specific events, such as the announcement of quarterly results, the extension and amendment of its Third Amended and Restated Loan and Security Agreement, and the reporting of preliminary full-year Adjusted EBITDA. One 8-K explains how American Vanguard defines EBITDA and Adjusted EBITDA, and why management uses these non-GAAP measures in assessing operating performance and in connection with its credit facility.
On this page, AI-generated summaries help explain the key points of lengthy filings, including how new loan amendments affect borrowing capacity, maturity dates, and financial covenants, or how non-recurring charges and product liability items are treated in reconciliations to Adjusted EBITDA. Users can also track governance-related filings, such as those reporting annual meeting voting results for directors, auditor ratification, and advisory compensation proposals.
By combining real-time EDGAR updates with concise AI explanations, this section allows readers to navigate American Vanguard’s SEC disclosures more efficiently, understand the context behind non-GAAP metrics, and follow the company’s financial and corporate developments as reported to regulators.
American Vanguard Corp (AVD): The Vanguard Group filed a Schedule 13G reporting beneficial ownership of 1,538,471 shares of AVD common stock, representing 5.41% of the class as of 09/30/2025.
Vanguard reports 0 sole voting power and 168,205 shared voting power. It has 1,360,046 shares with sole dispositive power and 178,425 with shared dispositive power. The filing states the securities are held in the ordinary course of business, and Vanguard’s clients have rights to dividends or sale proceeds; no single client has more than 5%.
Peter Eilers, a Managing Director at AMVAC Netherlands BV who is an officer and director of American Vanguard Corp (AVD), reported a sale of 6,000 shares of AVD common stock on 09/04/2025 at $5.35 per share to satisfy an income tax liability. After the transaction he beneficially owns 32,177 shares, held directly. The Form 4 discloses the transaction date, price, and a brief explanation that the sale was to cover taxes; no derivatives or other transactions were reported. The filing is routine disclosure of insider selling and does not include additional context about future transactions or company performance.
American Vanguard Corporation (AVD) filed a Form 144 to notify a proposed sale of securities under Rule 144. The notice reports 6,000 shares of common stock offered for sale through Merrill Lynch, Newport Beach, with an aggregate market value of $32,078.56 based on the filing. The proposed sale date is 09/04/2025 on the NYSE.
The shares were acquired as a performance award from American Vanguard Corp on 01/01/2020 and no securities of the issuer have been reported sold by the seller in the past three months. The filer affirms no undisclosed material adverse information.
American Vanguard Corporation filed a Current Report on Form 8-K disclosing an Amendment Number Twelve to the Third Amended and Restated Loan and Security Agreement dated August 18, 2025, involving the registrant, AMVAC Chemical Corporation, certain direct and indirect subsidiaries, and the senior lending group parties. The filing references a press release dated August 19, 2025 and includes an interactive Inline XBRL cover page data file. The report is signed by Timothy J. Donnelly, Chief Information Officer, General Counsel & Secretary. The document does not include the economic terms or covenant changes of the amendment within the provided text.
Keith M. Rosenbloom, a director of American Vanguard Corporation (AVD), reported an acquisition on 08/07/2025 of 17,621 deferred stock units (DSUs) awarded under the company’s non-management director compensation program. Each DSU represents the right to one share of common stock upon settlement when the recipient’s service ends; DSUs are nontransferable and do not carry voting or dividend rights during service. Following the award, Mr. Rosenbloom reports 34,411 shares beneficially owned directly and an indirect interest in 789,284 shares held by funds and separately managed accounts advised by Cruiser Capital, where he is Managing Member. The Form 4 was signed on 08/14/2025.
American Vanguard Corp (AVD) amended an insider Form 4 to correct previously reported holdings and explain changes in advisory authority. The filing discloses a disposition of 16,790 shares and states that a client of a separately managed account terminated its advisory agreement, removing Cruiser Capital's discretionary voting and dispositive authority over 411,398 shares; the termination involved no buy or sell transactions. The amendment corrects an earlier misstatement that reported 652,792 indirectly held shares; the filing clarifies the correct indirect holding is 789,284 shares.
Mark R. Bassett, a director of American Vanguard Corporation (AVD), reported the award of 17,621 deferred stock units (DSUs) on 08/07/2025 as part of the company’s non-management director compensation program. The DSUs are granted at $0, are nontransferable during the recipient’s service, and represent the right to receive one share of common stock upon settlement when the recipient’s service ends.
Following the award, the form shows 34,411 shares/units beneficially owned by the reporting person. No derivative securities were reported and the filing was submitted as an individual Form 4 by the director.
Carmen Tiu de Mino, a director of American Vanguard Corporation (AVD), was awarded 17,621 deferred stock units on 08/07/2025 as part of the company's non-management director compensation program. Each deferred stock unit (DSU) entitles the holder to one share upon settlement when the recipient's service with the company ends; DSUs are nontransferable and carry neither voting nor dividend rights during the remaining term of service.
Following the award, the reporting person beneficially owned 24,407 shares on a direct basis. The DSUs were issued at a recorded price of $0 and are subject to the company's standard DSU agreement.
Marisol Angelini, a director of American Vanguard Corp (AVD), reported on Form 4 that she was awarded 17,621 shares of common stock on 08/07/2025 as part of the companys compensation program for non-management directors related to the 2025 annual stockholders meeting. The award is reported at a price of $0 in the filing and is explained in an accompanying footnote.
Following the award, Angelini beneficially owns 36,890 shares. The Form 4 was signed on 08/08/2025 and filed by one reporting person. No derivative transactions are listed in Table II.
Gunter Emer, a director of American Vanguard Corporation (AVD), reported receiving 8,810 shares of common stock on 08/07/2025 as part of the company’s non-management director compensation program. The award was issued at $0 and increased his direct beneficial ownership to 33,723 shares.
The Form 4 shows no derivative securities and records the filing signature on 08/08/2025. The disclosure reflects a routine director equity award tied to the 2025 annual stockholders’ meeting rather than a market purchase or sale.